NEW YORK, Jan. 12, 2016 - The Nasdaq Stock Market (“Nasdaq”) announced today that, pursuant to Listing Rule 5815(a)(1)(B), KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) will be suspended from Nasdaq effective January 13, 2016.
Trading in the Company’s securities has been halted since December 17, 2015. The trading halt will no longer be in effect upon the suspension of KaloBios from Nasdaq, which would allow the Company’s securities to be eligible for trading in the over-the-counter markets under the symbol “KBIOQ.”
A hearing is scheduled for February 25, 2016, to review the company’s appeal of Nasdaq’s December 18, 2015 delist determination.
For news and additional information about the Company, including whether the Company’s securities will trade on another venue, please review the Company’s public filings or contact the Company directly.
For more information about Nasdaq trade halts, visit www.nasdaqtrader.com. For more information about the Nasdaq delisting process, visit listingcenter.nasdaq.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Instagram Outage Disrupts Thousands of U.S. Users
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



